Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 47.79% | -7.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 47.79% | -7.58% | |||
| Cost of Revenue | -26.59% | 152.30% | |||
| Gross Profit | 157.53% | -113.92% | |||
| SG&A Expenses | 10.05% | -6.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.10% | 4.85% | |||
| Operating Income | 75.26% | -19.23% | |||
| Income Before Tax | 33.12% | -191.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.12% | -191.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.12% | -191.98% | |||
| EBIT | 75.26% | -19.23% | |||
| EBITDA | 77.05% | -19.59% | |||
| EPS Basic | 80.07% | -172.06% | |||
| Normalized Basic EPS | 80.07% | -172.06% | |||
| EPS Diluted | 80.07% | -172.06% | |||
| Normalized Diluted EPS | 80.07% | -172.06% | |||
| Average Basic Shares Outstanding | 235.58% | 27.63% | |||
| Average Diluted Shares Outstanding | 235.58% | 27.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||